ATE425740T1 - Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom - Google Patents

Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom

Info

Publication number
ATE425740T1
ATE425740T1 AT06779382T AT06779382T ATE425740T1 AT E425740 T1 ATE425740 T1 AT E425740T1 AT 06779382 T AT06779382 T AT 06779382T AT 06779382 T AT06779382 T AT 06779382T AT E425740 T1 ATE425740 T1 AT E425740T1
Authority
AT
Austria
Prior art keywords
delivery system
chronotherapeutic
treatment
occular
prostaglandins
Prior art date
Application number
AT06779382T
Other languages
English (en)
Inventor
Barbara Conway
Doina Gherghel
Original Assignee
Univ Aston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0519270A external-priority patent/GB0519270D0/en
Priority claimed from GB0608181A external-priority patent/GB0608181D0/en
Application filed by Univ Aston filed Critical Univ Aston
Application granted granted Critical
Publication of ATE425740T1 publication Critical patent/ATE425740T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06779382T 2005-09-21 2006-09-11 Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom ATE425740T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0519270A GB0519270D0 (en) 2005-09-21 2005-09-21 Chronotherapeutic delivery system for treatment of glaucoma
GB0608181A GB0608181D0 (en) 2006-04-25 2006-04-25 Chronotherapeutic Delivery System For Treatment Of Glaucoma

Publications (1)

Publication Number Publication Date
ATE425740T1 true ATE425740T1 (de) 2009-04-15

Family

ID=37605837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06779382T ATE425740T1 (de) 2005-09-21 2006-09-11 Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom

Country Status (6)

Country Link
US (1) US20090155338A1 (de)
EP (1) EP1928407B1 (de)
AT (1) ATE425740T1 (de)
DE (1) DE602006005826D1 (de)
ES (1) ES2326282T3 (de)
WO (1) WO2007034140A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100233241A1 (en) * 2009-03-13 2010-09-16 Vista Scientific Llc Ophthalmic drug delivery system and applications
AU2010249683B2 (en) 2009-05-18 2015-06-25 Glaukos Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
AU2010256558B2 (en) 2009-06-03 2013-10-03 Forsight Labs, Llc Anterior segment drug delivery
AU2011256259A1 (en) 2010-05-17 2012-11-08 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
EP2654715B1 (de) 2010-11-24 2017-01-25 Dose Medical Corporation Arzneimittelfreisetzendes augenimplantat
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
AU2012308317B2 (en) 2011-09-14 2017-01-05 Forsight Vision5, Inc. Ocular insert apparatus and methods
SI2911623T1 (sl) 2012-10-26 2019-12-31 Forsight Vision5, Inc. Oftalmični sistem za podaljšano sproščanje zdravila v oko
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CA2950187A1 (en) 2014-05-29 2015-12-03 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP3283004A4 (de) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Augeneinsatzzusammensetzung aus einem semikristallinen oder kristallinen pharmazeutischen wirkstoff
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3442479A1 (de) 2016-04-20 2019-02-20 Harold Alexander Heitzmann Vorrichtung zur verabreichung eines bioresorbierbaren okularen medikaments
US11672697B2 (en) 2018-06-19 2023-06-13 Twenty Twenty Therapeutics Llc Eye-mountable therapeutic devices, and associated systems and methods
US11395797B2 (en) * 2019-12-10 2022-07-26 Alcon Inc. Dissolvable polymeric eye inserts with a biodegradable polymer and method of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
MXPA05000632A (es) * 2002-07-15 2005-03-31 Alcon Inc Composiciones para implante farmaceuticas, lipofilas, no polimericas para uso intraocular.
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods

Also Published As

Publication number Publication date
EP1928407B1 (de) 2009-03-18
WO2007034140A1 (en) 2007-03-29
EP1928407A1 (de) 2008-06-11
US20090155338A1 (en) 2009-06-18
ES2326282T3 (es) 2009-10-06
DE602006005826D1 (de) 2009-04-30

Similar Documents

Publication Publication Date Title
ATE425740T1 (de) Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primarem glaukom
DE602007004486D1 (de) Verwendung einer hydrophilen matrix mit einem polyacrylsäurederivat, einem celluloseether und einem sprengmittel zur herstellung eines medikaments zur behandlung von erkrankungen der weiblichen genitalorgane
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
JP2003505422A5 (de)
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
RU2014133501A (ru) Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением
MY208662A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
NZ734050A (en) Compositions comprising povidone-iodine
DE502004010303D1 (de) Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
DE102005053680A1 (de) Synergistische insektizide Mischungen zur Behandlung von Saatgut
ATE336247T1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
RU2004134733A (ru) Агенты, которые регулируют, ингибируют или модулируют активность и/или экспрессию факторов роста соединительной ткани (фрст), в качестве уникальных средств для снижения внутриглазного давления и лечения глаукоматозных ретинопатий/оптических невропатий
ATE554747T1 (de) Hochviskose makromolekulare zusammensetzungen zur behandlung von augenerkrankungen
ATE482726T1 (de) Neuartiges mittel zur freisetzung von wirkstoffen in dressings mit mindestens einer fettigen substanz
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
MX2009005332A (es) Composicion de control del daño producido por enfermedad de plantas y metodo de prevencion y control del daño producido por enfermedad de plantas.
NZ598271A (en) Use of sarmentine and its analogs for controlling plant pests
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
CL2011001219A1 (es) Composicion que comprende a): 2-[2-(2,5 dimetilfenoximetil)fenil)-2-metoxi-n-metilaceta-mida y b): metconazol o ipconazol, en una relacion en peso de a:b entre 0,0125:1 a 500: 1, y metodo que la aplica a semillas, una planta o el sitio para crecimiento de la planta para asi protegerlas del daño causado por plagas fitopatogenas.
EP4470615A3 (de) Kleine rna als medikament zur vorbeugung und behandlung entzündungsbedingter erkrankungen und kombination davon
WO2008005407A3 (en) Trace amine-associated receptors in the olfactory epithelium
EA201790382A1 (ru) Способы лечения периимплантита
ATE309796T1 (de) Verfahren zur behandlung von augenerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties